Advanced Search
Displaying 41-50 on page 5 of 93. Per Page  

Articles / Online

  • Les nouvelles techniques diagnostiques des tumeurs neuroendocrines pancréatiques*
    The New Diagnostic Techniques for Pancreatic Neuroendrocine Tumours
  • Abstract Pancreatic neuroendocrine tumours are the tumours developed at the expense of pancreas and require a specific diagnostic assessment. The imaging assessment of a pancreatic neuroendocrine tumour is useful for diagnosis as well as for surgical/medical treatment. Recently, a number of advances have been made in the field of imaging pancreatic neuroendocrine tumours, in particular in functional imaging using radiolabelled somatostatin analogues. In this review, we approach diagnostic progress by focusing on the advances of recent years. Thus, the interest of conventional imaging (scanner, abdominal ultrasound, and magnetic resonance imaging), ultrasound endoscopy and the place of functional imaging mainly with radiolabelled…
  • More
  •   Views:292       Downloads:374        Download PDF
  • AACR 2019 — Congrès de l’association américaine de recherche contre le cancer
    AACR 2019 — American Association for Cancer Research
  • Abstract In this special issue of Oncology, we have summarized the most relevant topics that were presented at the American Association for Cancer Research (AACR) meeting. Our purpose here is to give the readers a concise report of the presentations that warrant particular attention. This year 2019 in Atlanta, the AACR Annual Meeting program covered the latest discoveries across the spectrum of cancer research — from population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy — and highlights the work of the best minds in research and medicine from institutions all over the world. It…
  • More
  •   Views:303       Downloads:320        Download PDF
  • Place des CTC et de l’ADN circulant dans la prise en charge du cancer du sein
    CTC and cDNA in Breast Cancer Management
  • Abstract It has been known for a long time that circulating tumor cells (CTC) as well as circulating tumor DNA (ctDNA) can be detected. However, only recent technical advances allowed evaluating the interest of CTC and ctDNA in breast cancer. In both early and metastatic breast cancers, CTC detection is a recognized factor for poor outcome. Nevertheless, CTC detection does not impact cancer management yet. The use of ctDNA in daily practice will require validation by prospective data. But ctDNA seems particularly promising both for residual disease evaluation and identification of tumor clones harbouring mutations (PI3KC, ESR1) and may predict efficacy…
  • More
  •   Views:333       Downloads:280        Download PDF
  • Cancers du sein triple-négatifs : données actuelles et perspectives d’avenir
    Triple-Negative Breast Cancer: Current Data and Future Prospects
  • Abstract Triple-negative breast cancer (TNBC), defined by the lack of expression of hormone receptors and HER2 (Human Epidermal growth factor Receptor-2), accounts for 15–20% of breast cancers. However, this definition, which is essentially negative, masks the large biological heterogeneity of this subtype. While chemotherapy is the main established systemic treatment in both early and advanced stages of the disease, the progressive understanding of the molecular components involved in the pathogenesis of TNBC allows innovative therapeutic perspectives. The objective of this review is to describe these potential targets and to explore current and future treatments that will help fighting this cancer with…
  • More
  •   Views:386       Downloads:630        Download PDF
  • Mutations du gène ESR1 : du fondamental à la clinique
    ESR1 Mutations: From Benchside to Bedside
  • Abstract Acquired endocrine resistance remains one of the main obstacles in the treatment of estrogen receptor (ER) positive, HER2 negative advanced breast cancer. Recently, activating ESR1 gene mutations affecting the ligand-binding domain have been identified as a key mechanism in aromatase inhibitor (AI) resistance. These mutations can be detected on histological samples or circulating tumour DNA, using PCRbased assays or next-generation sequencing. They induce a constitutive activation of ER, leading to acquired resistance to AI; tamoxifen, fulvestrant and targeted therapies against mTOR or CDK4/6 retain their efficacy. The use of monitoring ESR1 mutations in clinical practice is still to be defined.…
  • More
  •   Views:282       Downloads:396        Download PDF
Displaying 41-50 on page 5 of 93. Per Page